Novartis (NOVN: VX) has described the findings of its trial of CTL019 in children and young adults with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) as a sign of “exciting progress.”
The Swiss pharma giant has presented results from its ELIANA trial evaluating the efficacy and safety of this investigational chimeric antigen receptor T cell (CAR-T) therapy at the 8th American Society of Hematology (ASH) annual meeting.
"This first-of-its-kind trial represents exciting progress toward our goal of helping children and young adults with relapsed or refractory B-cell ALL, a patient population with an urgent need for new treatment options"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze